Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Johnell O, Jonsson B, Jonsson L, Black D. Cost effectiveness of alendronate (Fosamax (R)) for the treatment of osteoporosis and prevention of fractures. PharmacoEconomics 2003; 21(5): 305-314 Indexing Status Subject indexing assigned by NLM MeSH Age Factors; Aged; Alendronate /economics /therapeutic use; Cohort Studies; Cost-Benefit Analysis; Female; Fractures, Bone /economics /prevention & Humans; Markov Chains; Osteoporosis, Postmenopausal /drug therapy /economics /mortality; Quality of Life; Quality-Adjusted Life Years; Sweden; Time Factors; control AccessionNumber 22003008111 Date bibliographic record published 04/04/2003 |